Sort   by:  
 Page size 
MetabolomicsMethionine Intervention Induces PD-L1 Expression to Enhance the Immune Checkpoint Therapy Response in MTAP-deleted Osteosarcoma
Osteosarcoma (OS), a malignant bone tumor with limited treatment options, exhibits low sensitivity to immune checkpoint therapy (ICT). Through genomics and transcriptomics analyses, we have identified a subgroup of OS with methylthioadenosine phosphorylase (MTAP) deletion, which contributes to ICT r...
2026-06-09 | MTBLS11985 | MetaboLights
MetabolomicsCeramide Disrupts TM9SF2-PGK1 Axis to Redirect PD-L1 Trafficking and Enhance Antitumor Immunity

The PD-1/PD-L1 axis represents a cornerstone of cancer immunotherapy, yet the dynamic shuttling of PD-L1 between endosomal recycling and lysosomal degradation routes limits durable responses. Using a CRISPR screen targeting glycosphingolipid metabolism, we identify TM9SF2 as a key regulator of PD...

2026-02-05 | MTBLS13838 | MetaboLights
ProteomicsPD-L1 intracellular interactions that necessitate the TSS motif within the cytoplasmic domain
Lymphatic endothelial cells (LEC) comprise lymphatic vessels that guide immune cells to lymph nodes (LN) and form the subcapsular sinus and cortical and medullary lymphatic structures of the LN. During an active immune response the lymphatics remodel to accommodate the influx of immune cells from th...
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2022-06-01 | MSV000089579 | MassIVE
ProteomicsThe major lysine residues of PD-L1 ubiquitinated by ARIH1
To figure out the major lysine residues of PD-L1 ubiquitinated by ARIH1, mass spectrometry was utilized to identify the ubiquitination site. K271 was identified as the major residues of ubiquitination
ORGANISM(S): Homo sapiens (Human) 
2025-08-25 | PXD063222 | Pride
Pd-l1 Arih1 
MetabolomicsChanges in L-phenylalanine concentration reflect and predict response to anti-PD-1 treatment combined with chemotherapy in patients with non-small cell lung cancer
Chemotherapy combined with checkpoint blockade antibodies targeting programmed cell death protein (PD-1) has achieved remarkable success in non-small cell lung cancer (NSCLC). However, few patients benefit from long-term treatment. Therefore, biomarkers capable of guiding the optimal therapeutic sel...
2025-06-16 | MTBLS11232 | MetaboLights
ProteomicsCell surface interactome analysis identifies TSPAN4 as a negative regulator of PD-L1 in melanoma
PD-L1 functions as a co-inhibitory checkpoint ligand constraining anti-tumor immunity by binding to PD-1 on immune cells. Although antibody blockade therapy displays clear therapeutic responses, it is not effective in all cancer patients, indicating modulation by other factors. We applied cell surfa...
ORGANISM(S): Homo sapiens (Human) 
2026-01-16 | PXD064698 | Pride
Tspan4 Pd-l1 Melanoma Surface proximity biotinylation 
ProteomicsBranched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC
Immunotherapy has revolutionized cancer treatment, however, a reliable biomarker is missing. MGAT5-mediated PD-L1 glycosylation is critical for its interaction with PD-1. MGAT5 expression is a functional biomarker that predicts immunotherapy responses.
ORGANISM(S): Homo sapiens (Human) 
2025-05-06 | PXD045506 | Pride
Mgat5 Immunotherapy N-glycosylation Pd-l1 Head and neck squamous cell carcinoma (hnscc) 
TranscriptomicsAnalysis of mouse T cell transcription profile after co-culture with BaF3 cells with or without the oncogenic point mutation JAK2 V617F
The activation of PD-1 (Programmed Death receptor-1) on T cells can cause T cell exhaustion and immune tolerance. Some tumors up-regulate the expression of the ligand of PD-1, namely PD-L1 (Programmed Death Receptor-Ligand 1), thus preventing anti-tumor immune response and promoting immune-escape. P...
ORGANISM(S): Mus musculus 
2018-12-01 | E-MTAB-5028 | biostudies-arrayexpress
ProteomicsLC-MS characterization of anti-PD-L1 and CXCR4 bispecific nanobodies
Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer. Here, we designed a nanobody molecule with bi-targeting on PD-L1 and CXCR4, as both targets are overexpressed i...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD037102 | Pride
Nanobody Lc-ms Bispecific Protein Complete mw 
TranscriptomicsExpression data in PD-L1 positive and PD-L1 negative human melanoma samples
Blocking the PD-1/PD-L1 immunosuppressive pathway has shown promise in the treatment of certain cancers including melanoma. This study investigates differences in the gene expression profiles of human melanomas that do or do not display the immunosuppressive protein PD-L1. Further understanding of g...
ORGANISM(S): Homo sapiens 
2015-05-01 | E-GEOD-65041 | biostudies-arrayexpress
Sort   by:  
 Page size